EntryPoint Capital LLC Buys 51,524 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL)

EntryPoint Capital LLC grew its stake in AbCellera Biologics Inc. (NASDAQ:ABCL) by 44.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 168,682 shares of the company’s stock after purchasing an additional 51,524 shares during the quarter. EntryPoint Capital LLC owned approximately 0.06% of AbCellera Biologics worth $494,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of ABCL. Guardian Partners Inc. acquired a new stake in AbCellera Biologics during the fourth quarter worth approximately $5,413,000. Walleye Capital LLC acquired a new stake in AbCellera Biologics during the 3rd quarter worth approximately $668,000. Moloney Securities Asset Management LLC bought a new stake in AbCellera Biologics in the 4th quarter valued at $265,000. Erste Asset Management GmbH acquired a new position in AbCellera Biologics in the 3rd quarter valued at $162,000. Finally, HighTower Advisors LLC increased its position in AbCellera Biologics by 577.9% during the 4th quarter. HighTower Advisors LLC now owns 71,086 shares of the company’s stock worth $208,000 after buying an additional 60,600 shares during the period. Institutional investors and hedge funds own 61.42% of the company’s stock.

AbCellera Biologics Stock Performance

Shares of NASDAQ ABCL opened at $2.53 on Wednesday. The stock has a market capitalization of $753.91 million, a P/E ratio of -4.15 and a beta of 0.45. The stock’s fifty day moving average is $2.89 and its 200 day moving average is $2.82. AbCellera Biologics Inc. has a 52 week low of $2.11 and a 52 week high of $4.75.

Analysts Set New Price Targets

ABCL has been the topic of several research reports. Benchmark restated a “hold” rating on shares of AbCellera Biologics in a research note on Monday, March 3rd. KeyCorp decreased their target price on shares of AbCellera Biologics from $5.00 to $4.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Finally, Stifel Nicolaus dropped their price target on shares of AbCellera Biologics from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, February 28th.

AbCellera Biologics Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.